Relative prevalence of high risk HPV genotypes in a US population: insights before rollout of the next generation 9-valent HPV vaccine

Huh, Warner

35
Relative prevalence of high risk HPV genotypes in a US population: insights before rollout of the next generation 9-valent HPV vaccine

Sunday, March 29, 2015: 5:25 PM

International Ballroom (Hilton Chicago)

W. K. Huh¹, C. M. Behrens², J. Monsonego³, T. Cox⁴, M. T. Sandri⁵, P. S. Yap² and E. L. Franco⁶
¹University of Alabama at Birmingham, Birmingham, AL, ²Roche Molecular Systems, Pleasanton, CA, ³Institut du Col, Paris, France, ⁴University of California, Santa Barbara, CA, ⁵Istituto Europeo di Oncologia, Milan, Italy, ⁶McGill University, Montreal, QC, Canada

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

35
Relative prevalence of high risk HPV genotypes in a US population: insights before rollout of the next generation 9-valent HPV vaccine

35 Relative prevalence of high risk HPV genotypes in a US population: insights before rollout of the next generation 9-valent HPV vaccine

35
Relative prevalence of high risk HPV genotypes in a US population: insights before rollout of the next generation 9-valent HPV vaccine